51
|
Yan C, Yuanjie T, Zhengqun X, Jiayan C, Kongdan L. Neutrophil Gelatinase-Associated Lipocalin Attenuates Ischemia/Reperfusion Injury in an In Vitro Model via Autophagy Activation. Med Sci Monit 2018; 24:479-485. [PMID: 29367586 PMCID: PMC5793691 DOI: 10.12659/msm.908158] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Background The aim of this study was to investigate the protective effects of neutrophil gelatinase-associated lipocalin (NGAL) on hypoxia/reoxygenation (H/R) induced acute kidney injury (AKI) in vitro. Material/Methods We used NRK-52E cells and H/R treatments to mimic ischemia/reperfusion injury (IRI) in vitro. Experimental groups were: the control group, the H/R group, the 3-methyladenine (3-MA)+H/R group, the NGAL (0.25, 0.5, and 1 ug/mL)+H/R group, and the NGAL (0.25, 0.5, 1 ug/mL)+3-MA+H/R group. After 24 hours of culture, cell proliferation was analyzed by CCK-8 assay. Expression of LC3-II was detected by immunoblot assay. Autophagy was detected by electron microscopy. Results The expression of LC3-II was increased in the H/R group compared with normoxic condition (p<0.05) and proliferation also improved. Autophagy was significantly inhibited by 3-MA, with downregulated of LC3-II, followed by decreased cell viability (p<0.05). We further detected the effect of different doses of NGAL in H/R induced injury, and found that low doses of NGAL alone slightly increased LC3-II protein accumulation, and autophagy was further induced with higher dose of NGAL treatment. Meanwhile, cell viability assays showed induced cell survival. We found that in the NGAL+3-MA group, cell viability assays revealed reduced cell damage, followed concomitantly with depressed autophagy. The formulation of autophagosomes were correlated with LC3-II protein expression in each group. Conclusions Autophagy plays a renoprotective role in H/R injury, as well in AKI. NGAL might be related to attenuated tubular epithelial cell damage via adjusting autophagy.
Collapse
Affiliation(s)
- Cai Yan
- Department of Nephropathy, Hospital of Jiangsu Chinese People's Armed Police Force, Yangzhou, Jiangsu, China (mainland)
| | - Tang Yuanjie
- Department of Urology, Hospital of Jiangsu Chinese People's Armed Police Force, Yangzhou, Jiangsu, China (mainland)
| | - Xu Zhengqun
- Department of Nephropathy, Hospital of Jiangsu Chinese People's Armed Police Force, Yangzhou, Jiangsu, China (mainland)
| | - Chen Jiayan
- Department of Nephropathy, Hospital of Jiangsu Chinese People's Armed Police Force, Yangzhou, Jiangsu, China (mainland)
| | - Li Kongdan
- Department of Nephropathy, Hospital of Jiangsu Chinese People's Armed Police Force, Yangzhou, Jiangsu, China (mainland)
| |
Collapse
|
53
|
Martínez-Martínez E, Buonafine M, Boukhalfa I, Ibarrola J, Fernández-Celis A, Kolkhof P, Rossignol P, Girerd N, Mulder P, López-Andrés N, Ouvrard-Pascaud A, Jaisser F. Aldosterone Target NGAL (Neutrophil Gelatinase–Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NFκB Pathway. Hypertension 2017; 70:1148-1156. [DOI: 10.1161/hypertensionaha.117.09791] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2017] [Revised: 06/19/2017] [Accepted: 09/04/2017] [Indexed: 12/30/2022]
Affiliation(s)
- Ernesto Martínez-Martínez
- From the INSERM, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris Descartes University, France (E.M.-M., M.B., F.J.); Inserm U1096, UFR Médecine-Pharmacie, Rouen, France (I.B., P.M., A.O.-P.); Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain (J.I., A.F.-C., N.L.-A.); Cardiology Research, BAYER AG, Wuppertal, Germany (P.K.); and INSERM, Centre
| | - Mathieu Buonafine
- From the INSERM, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris Descartes University, France (E.M.-M., M.B., F.J.); Inserm U1096, UFR Médecine-Pharmacie, Rouen, France (I.B., P.M., A.O.-P.); Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain (J.I., A.F.-C., N.L.-A.); Cardiology Research, BAYER AG, Wuppertal, Germany (P.K.); and INSERM, Centre
| | - Ines Boukhalfa
- From the INSERM, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris Descartes University, France (E.M.-M., M.B., F.J.); Inserm U1096, UFR Médecine-Pharmacie, Rouen, France (I.B., P.M., A.O.-P.); Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain (J.I., A.F.-C., N.L.-A.); Cardiology Research, BAYER AG, Wuppertal, Germany (P.K.); and INSERM, Centre
| | - Jaime Ibarrola
- From the INSERM, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris Descartes University, France (E.M.-M., M.B., F.J.); Inserm U1096, UFR Médecine-Pharmacie, Rouen, France (I.B., P.M., A.O.-P.); Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain (J.I., A.F.-C., N.L.-A.); Cardiology Research, BAYER AG, Wuppertal, Germany (P.K.); and INSERM, Centre
| | - Amaya Fernández-Celis
- From the INSERM, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris Descartes University, France (E.M.-M., M.B., F.J.); Inserm U1096, UFR Médecine-Pharmacie, Rouen, France (I.B., P.M., A.O.-P.); Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain (J.I., A.F.-C., N.L.-A.); Cardiology Research, BAYER AG, Wuppertal, Germany (P.K.); and INSERM, Centre
| | - Peter Kolkhof
- From the INSERM, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris Descartes University, France (E.M.-M., M.B., F.J.); Inserm U1096, UFR Médecine-Pharmacie, Rouen, France (I.B., P.M., A.O.-P.); Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain (J.I., A.F.-C., N.L.-A.); Cardiology Research, BAYER AG, Wuppertal, Germany (P.K.); and INSERM, Centre
| | - Patrick Rossignol
- From the INSERM, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris Descartes University, France (E.M.-M., M.B., F.J.); Inserm U1096, UFR Médecine-Pharmacie, Rouen, France (I.B., P.M., A.O.-P.); Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain (J.I., A.F.-C., N.L.-A.); Cardiology Research, BAYER AG, Wuppertal, Germany (P.K.); and INSERM, Centre
| | - Nicolas Girerd
- From the INSERM, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris Descartes University, France (E.M.-M., M.B., F.J.); Inserm U1096, UFR Médecine-Pharmacie, Rouen, France (I.B., P.M., A.O.-P.); Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain (J.I., A.F.-C., N.L.-A.); Cardiology Research, BAYER AG, Wuppertal, Germany (P.K.); and INSERM, Centre
| | - Paul Mulder
- From the INSERM, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris Descartes University, France (E.M.-M., M.B., F.J.); Inserm U1096, UFR Médecine-Pharmacie, Rouen, France (I.B., P.M., A.O.-P.); Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain (J.I., A.F.-C., N.L.-A.); Cardiology Research, BAYER AG, Wuppertal, Germany (P.K.); and INSERM, Centre
| | - Natalia López-Andrés
- From the INSERM, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris Descartes University, France (E.M.-M., M.B., F.J.); Inserm U1096, UFR Médecine-Pharmacie, Rouen, France (I.B., P.M., A.O.-P.); Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain (J.I., A.F.-C., N.L.-A.); Cardiology Research, BAYER AG, Wuppertal, Germany (P.K.); and INSERM, Centre
| | - Antoine Ouvrard-Pascaud
- From the INSERM, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris Descartes University, France (E.M.-M., M.B., F.J.); Inserm U1096, UFR Médecine-Pharmacie, Rouen, France (I.B., P.M., A.O.-P.); Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain (J.I., A.F.-C., N.L.-A.); Cardiology Research, BAYER AG, Wuppertal, Germany (P.K.); and INSERM, Centre
| | - Frédéric Jaisser
- From the INSERM, UMRS 1138, Team 1, Centre de Recherche des Cordeliers, Pierre et Marie Curie University, Paris Descartes University, France (E.M.-M., M.B., F.J.); Inserm U1096, UFR Médecine-Pharmacie, Rouen, France (I.B., P.M., A.O.-P.); Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain (J.I., A.F.-C., N.L.-A.); Cardiology Research, BAYER AG, Wuppertal, Germany (P.K.); and INSERM, Centre
| |
Collapse
|